3 citations
,
February 2023 in “BMJ Case Reports” OnabotulinumtoxinA treatment improved hair-pulling disorder and hair regrowth in a woman with chronic migraines.
June 2023 in “Lithuanian University of Health Sciences” May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
January 2007 in “UNIFESP Institutional Repository (Universidade Federal de São Paulo)” Addressing anxiety and mood disorders is crucial to reduce medication overuse in chronic migraine patients.
December 2025 in “Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)” Botulinum toxin may reduce inflammation markers in head and neck conditions, but evidence is uncertain.
June 2023 in “medRxiv (Cold Spring Harbor Laboratory)” Nociplastic type pain, common in Chronic Overlapping Pain Conditions, is a complex, heritable trait linked to 24 unique genetic factors and 127 genes, with potential shared mechanisms in cognitive, personality, and metabolic traits.
1 citations
,
June 2025 in “Pharmacia” Botulinum toxin is effective for medical and cosmetic uses but requires careful handling to avoid serious side effects.
January 2023 in “Л.Н. Гумилев атындағы Еуразия ұлттық университетінің хабаршысы” Botulinum toxin is effectively used to treat various painful conditions and its therapeutic uses are growing.
March 2024 in “Indian Journal of Dermatology/Indian journal of dermatology” Using animal names for skin conditions helps with learning and memory.
April 2017 in “Journal of nutritional health & food engineering” Over 65% of people in the United Arab Emirates have undetected vitamin D deficiency, causing symptoms often mistaken for stress or migraines.
July 2005 in “CME: Your SA Journal of CPD” Botulinum toxin is a safe alternative for treating migraines without common side effects, but should be used after other treatments fail.
2 citations
,
January 2014 in “Medical Principles and Practice” The study suggests that people with rosacea are more likely to have chronic rhinosinusitis.
9 citations
,
January 2013 in “PubMed” Dihydrotestosterone might cause migraines, and finasteride could help reduce them.
22 citations
,
February 2023 in “European Journal of Neurology” Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
Botox is effective for urinary incontinence, chronic migraines, and male pattern hair loss, and a new test for Botox antibodies is more humane.
Onabotulinum toxin A may help treat trichotillomania and promote hair growth.
October 2022 in “Deleted Journal” Long-term low-dose Vitamin A intake may cause increased brain pressure.
6 citations
,
April 2017 in “InTech eBooks” New insights on headaches include genetics, smartphone impact, and botulinum toxin treatment.
April 2025 in “Revista de Ciências da Saúde Nova Esperança” Botulinum Toxin Type A effectively treats various conditions with high patient satisfaction and minimal side effects.
16 citations
,
December 2012 in “The Clinical Journal of Pain” Chronic scalp pain in trichodynia involves both body-wide and localized increased pain sensitivity.
72 citations
,
October 2010 in “Journal of The American Academy of Dermatology” Iron deficiency common in women, not always linked to hair loss; more research needed.
May 2025 in “The Journal of Rheumatology” Chronic granulomatous disease may be linked to developing systemic lupus erythematosus.
34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.
7 citations
,
January 2019 in “Headache” Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.
1 citations
,
January 2013 in “Mayo Clinic Proceedings” A woman's chronic headaches and hair loss were cured by treating her syphilis.
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
October 2025 in “Indian Journal of Physiology and Pharmacology” Early diagnosis and treatment of endocrine disorders like HAIR-AN syndrome can improve outcomes in adolescents.
January 2021 in “International Journal of Advanced Research in Medicine” Propranolol, flunarizine, and divalproex sodium are equally effective for preventing migraines, but have different side effects.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
16 citations
,
November 2024 in “Human Genetics and Genomics Advances” Nociplastic pain is a complex, heritable trait with genetic links to chronic and neuropathic pain.